Product Description
For Advanced Solid Tumor Patients With a BRAF V600 Mutation (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05275374)
Mechanisms of Action: BRAF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Xynomic
Company Location:
Company Founding Year: 2016
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colorectal Cancer|Melanoma|Non-Small-Cell Lung Cancer|Thyroid Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05275374 |
ENHANCE | P2 |
Not yet recruiting |
Colorectal Cancer|Non-Small-Cell Lung Cancer|Thyroid Cancer|Melanoma |
2027-12-30 |
12% |
2025-04-11 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/04/2020 |
News Article |
Advances in Treatments are Leading to a Decline in Deaths from Cancer |
|
09/23/2019 |
News Article |
Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma |
|
09/13/2019 |
News Article |
Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor |
|
08/30/2019 |
News Article |
Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors |